Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

Summary

The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.

Timeline

Start

2005-02

Primary completion

—

Completion

2007-08

Drugs

Indications